Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Conditions

• Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
• EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
• High Grade B-Cell Lymphoma, Not Otherwise Specified
• Large B-Cell Lymphoma With IRF4 Rearrangement
• Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
• Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
• Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
• Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
• Recurrent Intravascular Large B-Cell Lymphoma
• Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
• Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
• Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
• Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
• Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
• Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
• Refractory Intravascular Large B-Cell Lymphoma
• Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
• Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
• Refractory Transformed B-Cell Non-Hodgkin Lymphoma

Interventions

• BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy
• OTHER: Quality-of-Life Assessment
• OTHER: Questionnaire Administration
• DRUG: Zanubrutinib

Sponsor

Northwestern University

Collaborators

• [object Object]